Urology
Volume 67, Issue 6 , Pages 1247-1252 , June 2006

Prognostic significance of neuroendocrine expression in lymph node-positive prostate cancer

  • Marcus L. Quek

      Affiliations

    • Department of Urology, Loyola University Stritch School of Medicine, Maywood, Illinois
    • ,
  • Siamak Daneshmand

      Affiliations

    • Division of Urology, Oregon Health and Science University, Portland, Oregon
    • ,
  • Sonali Rodrigo

      Affiliations

    • Department of Pathology, University of Southern California Keck School of Medicine, Los Angeles, California, USA
    • ,
  • Jie Cai

      Affiliations

    • Department of Preventive Medicine, University of Southern California Keck School of Medicine, Los Angeles, California, USA
    • ,
  • Tanya B. Dorff

      Affiliations

    • Division of Medical Oncology, University of Southern California Keck School of Medicine, Los Angeles, California, USA
    • ,
  • Susan Groshen

      Affiliations

    • Department of Preventive Medicine, University of Southern California Keck School of Medicine, Los Angeles, California, USA
    • ,
  • Donald G. Skinner

      Affiliations

    • Department of Urology, University of Southern California Keck School of Medicine, Los Angeles, California, USA
    • ,
  • Gary Lieskovsky

      Affiliations

    • Department of Urology, University of Southern California Keck School of Medicine, Los Angeles, California, USA
    • ,
  • Jacek Pinski

      Affiliations

    • Division of Medical Oncology, University of Southern California Keck School of Medicine, Los Angeles, California, USA
    • Corresponding Author InformationReprint requests: Jacek Pinski, M.D., Ph.D., Division of Medical Oncology, University of Southern California Keck School of Medicine, Norris Comprehensive Cancer Center, 1441 Eastlake Avenue, Suite 3449, Los Angeles, CA 90033.

Received 25 March 2005 ,Accepted 2 December 2005.

References 

  1. Abrahamsson PA . Neuroendocrine differentiation in prostatic carcinoma . Prostate . 1999;39:135–148
  2. Jongsma J , Oomen MH , Noordzij MA , et al.   Androgen-independent growth is induced by neuropeptides in human prostate cancer cell lines . Prostate . 2000;42:34–44
  3. Bonkhoff H . Neuroendocrine cells in benign and malignant prostate tissue (morphogenesis, proliferation, and androgen receptor status) . Prostate Suppl . 1998;8:18–22
  4. Vashchenko N , Abrahamsson PA . Neuroendocrine differentiation in prostate cancer (implications for new treatment modalities) . Eur Urol . 2005;47:147–155
  5. Huss WJ , Gregory CW , Smith GJ . Neuroendocrine cell differentiation in the CWR22 human prostate cancer xenograft (association with tumor cell proliferation prior to recurrence) . Prostate . 2004;60:91–97
  6. di Sant’Agnese PA , Cockett AT . Neuroendocrine differentiation in prostatic malignancy . Cancer . 1996;78:357–361
  7. Abrahamsson PA , Falkmer S , Falt K , et al.   The course of neuroendocrine differentiation in prostatic carcinomas (an immunohistochemical study testing chromogranin A as an “endocrine marker.”) . Pathol Res Pract . 1989;185:373–380
  8. Abrahamsson PA , Wadstrom LB , Alumets J , et al.   Peptide-hormone- and serotonin-immunoreactive tumour cells in carcinoma of the prostate . Pathol Res Pract . 1987;182:298–307
  9. Guate JL , Escaf S , Menendez CL , et al.   Neuroendocrine cells in benign prostatic hyperplasia and prostatic carcinoma (effect of hormonal treatment) . Urol Int . 1997;59:149–153
  10. Krijnen JL , Bogdanowicz JF , Seldenrijk CA , et al.   The prognostic value of neuroendocrine differentiation in adenocarcinoma of the prostate in relation to progression of disease after endocrine therapy . J Urol . 1997;158:171–174
  11. Jiborn T , Bjartell A , Abrahamsson PA . Neuroendocrine differentiation in prostatic carcinoma during hormonal treatment . Urology . 1998;51:585–589
  12. Mori S , Murakami-Mori K , Bonavida B . Interleukin-6 induces G1 arrest through induction of p27(Kip1), a cyclin-dependent kinase inhibitor, and neuron-like morphology in LNCaP prostate tumor cells . Biochem Biophys Res Commun . 1999;257:609–614
  13. Spiotto MT , Chung TD . STAT3 mediates IL-6-induced neuroendocrine differentiation in prostate cancer cells . Prostate . 2000;42:186–195
  14. Deeble PD , Murphy DJ , Parsons SJ , et al.   Interleukin-6- and cyclic AMP-mediated signaling potentiates neuroendocrine differentiation of LNCaP prostate tumor cells . Mol Cell Biol . 2001;21:8471–8482
  15. Chen T , Cho RW , Stork PJ , et al.   Elevation of cyclic adenosine 3′,5′-monophosphate potentiates activation of mitogen-activated protein kinase by growth factors in LNCaP prostate cancer cells . Cancer Res . 1999;59:213–218
  16. Cox ME , Deeble PD , Bissonette EA , et al.   Activated 3′,5′-cyclic AMP-dependent protein kinase is sufficient to induce neuroendocrine-like differentiation of the LNCaP prostate tumor cell line . J Biol Chem . 2000;275:13812–13818
  17. Shen R , Dorai T , Szaboles M , et al.   Transdifferentiation of cultured human prostate cells to a neuroendocrine cell phenotype in a hormone-depleted medium . Urol Res . 1997;3:67–75
  18. Cohen RJ , Glezerson G , Haffejee Z , et al.   Prostatic carcinoma (histological and immunohistological factors affecting prognosis) . Br J Urol . 1990;66:405–410
  19. Weinstein MH , Partin AW , Veltri RW , et al.   Neuroendocrine differentiation in prostate cancer (enhanced prediction of progression after radical prostatectomy) . Hum Pathol . 1996;27:683–687
  20. Theodorescu D , Broder SR , Boyd JC , et al.   Cathepsin D and chromogranin A as predictors of long term disease specific survival after radical prostatectomy for localized carcinoma of the prostate . Cancer . 1997;80:2109–2119
  21. Cohen MK , Arber DA , Coffield KS , et al.   Neuroendocrine differentiation in prostatic adenocarcinoma and its relationship to tumor progression . Cancer . 1994;74:1899–1903
  22. Noordzij MA , van der Kwast TH , van Steenbrugge GJ , et al.   The prognostic influence of neuroendocrine cells in prostate cancer (results of a long-term follow-up study with patients treated by radical prostatectomy) . Int J Cancer . 1995;62:252–258
  23. Allen FJ , Van Velden DJ , Heyns CF . Are neuroendocrine cells of practical value as an independent prognostic parameter in prostate cancer? . Br J Urol . 1995;75:751–754
  24. Pruneri G , Galli S , Rossi RS , et al.   Chromogranin A and B and secretogranin II in prostatic adenocarcinomas (neuroendocrine expression in patients untreated and treated with androgen deprivation therapy) . Prostate . 1998;34:113–120
  25. Tan MO , Karaoglan U , Celik B , et al.   Prostate cancer and neuroendocrine differentiation . Int Urol Nephrol . 1999;31:75–82
  26. Daneshmand S , Quek ML , Stein JP , et al.   Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy (long-term results) . J Urol . 2004;172:2252–2255
  27. Bostwick DG , Qian J , Pacelli A , et al.   Neuroendocrine expression in node positive prostate cancer (correlation with systemic progression and patient survival) . J Urol . 2002;168:1204–1211
  28. Wang Q , Horiatis D , Pinski J . Inhibitory effect of IL-6-induced neuroendocrine cells on prostate cancer cell proliferation . Prostate . 2004;61:253–259
  29. Wang Q , Horiatis D , Pinski J . Interleukin-6 inhibits the growth of prostate cancer xenografts in mice by the process of neuroendocrine differentiation . Int J Cancer . 2004;111:508–513
  30. Aprikian AG , Cordon-Cardo C , Fair WR , et al.   Characterization of neuroendocrine differentiation in human benign prostate and prostatic adenocarcinoma . Cancer . 1993;71:3952–3965

PII: S0090-4295(05)01763-2

doi: 10.1016/j.urology.2005.12.009

Urology
Volume 67, Issue 6 , Pages 1247-1252 , June 2006

Article Tools